Régis Pierre Radermecker

The Smart MDI System in People With Type 1 Diabetes and High HBA1C: A Randomized Controlled Trial Demonstrating That Response to Alerts Drives Outcomes

ABSTRACT Aims The aim was to assess the efficacy and safety of the smart multiple daily injections (MDI) system versus MDI plus continuous glucose monitor (CGM) in people with Type 1 diabetes and HbA1c ≥ 8%. Material and Methods After a 3‐week run‐in, 143 participants were random...